Načítá se...

IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells

EGFR-mutated non-small cell lung cancer patients experience relapse within 1-2 years of treatment with EGFR-inhibitors, such as erlotinib. Multiple resistance mechanisms have been identified including secondary EGFR-mutations, MET-amplification, and epithelial-mesenchymal transition (EMT). Previous...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Hussmann, Dianna, Madsen, Anne Tranberg, Jakobsen, Kristine Raaby, Luo, Yonglun, Sorensen, Boe Sandahl, Nielsen, Anders Lade
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464869/
https://ncbi.nlm.nih.gov/pubmed/28418902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16350
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!